Global Familial Breast Cancer Treatment Market – Industry Trends and Forecast to 2029

Market Analysis and Size                              

According to the World Health Organization (WHO), the global incidence of breast cancer was 2,261,419 in 2020, accounting for around 11.7 percent of all cancer cases. A variety of factors that raise the risk of breast cancer have been found. A relative's history of breast cancer is one of the most powerful of these risk factors. About 15 percent to 20 percent of breast cancer patients have a family history of the disease, indicating that inherited (genetic) factors play a role in the development of some breast cancers. The breast cancer susceptibility genes BRCA1 and BRCA2 are thought to be responsible for 5% to 10% of all breast cancers.

Data Bridge Market Research analyses that the familial breast cancer treatment market was valued at USD 1.93 billion in 2021 and is expected to reach USD 5.17 billion by 2029, registering a CAGR of 13.10% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Breast cancer having a family history of one or more first- or second-degree relatives who have breast cancer that does not satisfy the HBC definition mentioned below is referred to as familial breast cancer (FBC). Chemotherapy, radiation, and immunosuppressive medicines are used to slow the spread of cancer throughout the body, but they can also harm healthy cells. Following harsh cancer therapies, some "second cancers" have been observed to develop that are wholly unrelated to the original malignancy. The use of chest radiation therapy to treat other diseases or tumors raises the risk of developing breast cancer.

Familial Breast Cancer Treatment Market Dynamics

Drivers

• Rising prevalence of familial breast cancer

The surging prevalence of familial breast cancer is expected to drive the market's growth rate during the forecast period of 2022-2029. According to the Indian Council of Medical Research (ICMR), India is estimated to have 17.3 lakh new cancer cases by 2020, with over 8.8 lakh people dying from the disease. Breast cancer, which has the highest incidence of all cancer in women, has grown more common among those under the age of 50. Familial breast cancer (FBC) is a subtype of breast cancer that has a genetic component, accounting for about 5%–10% of all cases.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of familial breast cancer treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Changing lifestyle of people

Breast cancer can also be caused by lifestyle decisions. Poor diet, inactivity, obesity, heavy alcohol consumption, tobacco consumption, smoking, and exposure to chemicals and pollutants are linked to an increased risk of breast cancer. All these factors are anticipated to increase the demand for the familial breast cancer treatment market during 2022-2029.

Furthermore, rising government initiatives to spread awareness and increasing the geriatric population will result in the expansion of the familial breast cancer treatment market. Along with this, favourable reimbursement policies and surging adoption rate of early diagnosis will enhance the market's growth rate.

Opportunities

• Increase in the number of research and development activities       

The market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the familial breast cancer treatment market growth. Due to its multiple medical and societal ramifications, familial breast cancer has received a lot of attention in recent years. Following the discovery of the tumor suppressor genes BRCA1 and BRCA2, as well as the increased risk of breast cancer associated with mutations in these genes, a number of studies have looked into the nature of this risk and the diagnostic and therapeutic procedures that have been suggested to reduce the incidence of breast and ovarian cancer in this population.

• Technological advancement in diagnostic methods

The rising technological advancement in diagnostic methods is expected to create new market opportunities. For instance, in the field of cancer diagnostics, Direct-To-Consumer (DTC) testing was introduced. The first DTC test for BRCA testing, developed by 23andMe in 2018, got FDA approval in the United States. It's one of the first direct-to-consumer testing for BRCA gene abnormalities, which raise the risk of breast and ovarian cancer.

Moreover, the market's growth is fueled by increasing reimbursement and insurance coverage and emerging new markets. These factors will provide beneficial opportunities for the familial breast cancer treatment market growth.

Restraints/Challenges

On the other hand, high cost associated with the available treatment and diagnosis will obstruct the growth rate of the market. The lack of healthcare infrastructure in developing economies and dearth of skilled professionals will challenge the familial breast cancer treatment market. Additionally, lack of awareness about rare diseases and unfavourable healthcare policies will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This familial breast cancer treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the familial breast cancer treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Familial breast cancer treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Familial Breast Cancer Treatment Market

The COVID-19 pandemic has become a major public health concern, slowing the growth of the breast cancer treatments market. The coronavirus outbreak has wreaked havoc on the world economy, causing economic hardship and financial hardship. Many industries, including healthcare, witnessed significant changes. Other medical treatments were postponed while hospital admissions for COVID-19 impacted individuals were priority. According to an essay published by the National Centers for Biotechnology Information (NCBI), the COVID-19 pandemic in 2021 prompted breast cancer screening and treatment delays due to fear of infection and lockdown. According to the study, the number of breast cancer patients admitted dropped by 15% during the coronavirus outbreak.

The rising incidence of breast cancer and increased death rate among breast cancer patients with acquired COVID-19 infection, on the other hand, are anticipated to boost market size. Additionally, the reduction of COVID-19 instances and government attempts to ease the treatment of breast cancer patients would help market statistics. As a result of the delayed detection and treatment of breast cancer, the market grew slowly, while the market is estimated to continue to rise in the coming years.

Recent Development

• In March 2022, AstraZeneca and MSD announced the US Food and Drug Administration (FDA) approval for Lynparza in the US as adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. Adult patients with deleterious or suspected deleterious gBRCAm HER2-negative high-risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy can now receive Lynparza as an adjuvant treatment.

Global Familial Breast Cancer Treatment Market Scope

The familial breast cancer treatment market is segmented on the basis of route of administration, diagnosis, treatment, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Chemotherapy
• Radiation Therapy
• Genetic Counseling
• Medication
• Immunosuppressive drugs
• Others
• Others

Diagnosis

• Genetic Testing
• Magnetic Resonance Imaging (MRI)
• Mammography
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Familial Breast Cancer Treatment Market Regional Analysis/Insights

The familial breast cancer treatment market is analysed and market size insights and trends are provided by country, route of administration, diagnosis, treatment, end-users and distribution channel as referenced above.

The countries covered in the familial breast cancer treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the familial breast cancer treatment market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the growing prevalence of breast cancer and rising healthcare expenditure will further propel the market's growth rate in this region. Additionally, the growing presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period of 2022-2029 due to the development of healthcare infrastructure in this region. Also, rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Familial Breast Cancer Treatment Market Share Analysis

The familial breast cancer treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to familial breast cancer treatment market.

Some of the major players operating in the familial breast cancer treatment market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Bayer AG (Germany)
• Eli Lilly and Company (U.S.)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• AbbVie Inc. (U.S.)
• Johnson & Johnson Private Limited (U.S.)
• Cipla Inc. (U.S.)  
• Abbott (U.S.)
• Merck KGaA (Germany)
• LEO Pharma A/S (Denmark)
• Bausch Health Companies Inc. (Canada)
• Sun Pharmaceutical Industries Ltd. (India)
• Aurobindo Pharma (India)
• Lupin (India)
• Hikma Pharmaceuticals PLC (U.K.)
• Fresenius Kabi AG (Germany)
• Amneal Pharmaceuticals LLC. (U.S.)

SKU-68636